Pediatric Primary Care Case Studies (148 page)

iPLEDGE program,
473

iron deficiency anemia.
See
IDA (iron deficiency anemia)

isotretinoin (Accutane),
473
,
477
t

itchy rash,
455
–466

AD (atopic dermatitis),
455
–464

antibiotics for,
462
–463

antivirals for,
463

Atopiclair for,
463

diagnosis of,
456
,
459

differential diagnosis for,
459

epidemiology/etiology of,
456

follow-up visits for,
463
–464

history-taking,
459

management of,
459
–464

medications for,
460
–463,
461
t

MimyX for,
463

parental/patient education for,
463
–464

pathophysiology of,
457

physical examination,
456
,
459

presentation of,
457
–458

PUVA therapy for,
462

RAST/SPT,
458

systemic steroids for,
462

TCIs for,
462

topical corticosteroids for,
460
–462,
461
t

triggers of,
458
–459

case presentation for,
455
,
459
,
463
–464

fundamental contexts of,
455
–456,
464

objectives for,
455

resources for,
465
–466

J

JRA (juvenile rheumatoid arthritis),
484
–487

K

ketotifen fumarate (Zaditor),
343
t

Kinsey Institute studies,
225
–226

Klebsiella pneumoniae
,
421

L

language/social delays (toddlers),
27
–42

ASDs,
28
–40,
29
t,
30
f

AAP screen recommendations for,
27
–28,
35
,
39

ABA and,
37
–38

AD,
28
,
30
f

AS,
28

CARS and,
37

CHAT and,
35

diagnosis of,
33
–37,
34
b

diagnostic testing for,
35
–37,
36
f

DSM-IV-TR
criteria for,
30
f

epidemiology/etiology of,
28
–31

history-taking for,
31
–32

M-CHAT and,
35
,
36
f

management of,
37
–39

PDD-NOS,
28

PDDST-II and,
35

physical examinations for,
33

prognosis for,
39

TEACCH and,
37
–38

case presentation for,
27
–28

developmental milestones and,
28
,
29
t

fundamental contexts of,
27
–28,
39

objectives for,
27

plans for,
37
–39

diagnostic,
37

educational,
37
–39

intervention,
37
–38

resources for,
40
–41,
40
b

late-preterm infants (well-child care),
493
–506.
See also
well-child care

case presentation for,
493
,
496
–501,
504

diagnosis of,
496
–501

cultural/teenage dynamics,
499

diagnostic testing,
501

differential,
500
–501

history-taking,
496
–499

physical examination,
500

social/emotional history,
499
–500

epidemiology/etiology of,
494
–496

common issues,
495
–496

definitions,
494

hyperbilirubinemia,
494
–495

jaundice,
494
–495

lung function,
494

metabolic function,
495

sepsis,
494

temperature regulation,
495

fundamental contexts for,
493
,
505

management of,
501
–504

follow-up visits,
504
–505

immunizations,
503
–504

parent education,
502
–504

referrals,
503

therapeutic plans,
501
–502

objectives for,
493

resources for,
505
–506

law enforcement authorities,
194
–200,
203

LCPD (Legg-Calve-Perthes disease),
484
–487

lead poisoning,
303
–305,
309

Legg-Calve-Perthes disease.
See
LCPD (Legg-Calve-Perthes disease)

lesbian issues.
See
LGBT (lesbian, gay, bisexual, and transgendered) issues

leukemia,
305
–306

leukemia, lymphoblastic,
486
–487

levocabastine HCl (Livostin),
343
t

Lexapro.
See
escitalopram (Lexapro)

LGBT (lesbian, gay, bisexual, and transgendered) issues,
221
–231

adolescent sexual expression,
225
–227

American Community Survey,
225

epidemiology/etiology of,
225
–227

Kinsey Institute studies,
225
–226

case presentation for,
221
,
224
–229